Improvement of necrobiosis lipoidica with topical ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream

Shannon Nugent; Alexandra J Coromilas; Joseph C English 3rd; Misha Rosenbach

doi:10.1016/j.jdcr.2022.08.028

Improvement of necrobiosis lipoidica with topical ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream

JAAD Case Rep. 2022 Aug 27:29:25-26. doi: 10.1016/j.jdcr.2022.08.028. eCollection 2022 Nov.

Authors

Shannon Nugent¹, Alexandra J Coromilas², Joseph C English 3rd³, Misha Rosenbach²

Affiliations

¹ Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
² Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
³ Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

No abstract available

Keywords: JAK inhibitor; JAK, Janus kinase; Janus kinase; NL, necrobiosis lipoidica; STAT, signal transducer and activator of transcription; granulomatous disorders; necrobiosis lipoidica; ruxolitinib; tofacitinib.

Publication types

Case Reports